Quadmedicine: 투자판단관련주요경영사항(임상시험계획승인신청)

September 14, 2026 · KOSDAQ · Market cap ₩51.2bn · Quadmedicine chart & price →
AI reading
★★★ Neutral · Material event

알레르기 반응 응급치료제 임상 1상 계획 승인 신청

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

All of today's important filings (Filings Radar) →

For information only. Not investment advice.